89bio
Social media
89bio Logo
About 89bio
89bio Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardiometabolic diseases. Its lead product candidate, pegozafermin, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The company aims to address unmet medical needs by advancing novel treatments for patients with limited or no approved therapeutic options. 89bio is headquartered in San Francisco, California.
Address
142 Sansome Street, Second Floor
San Francisco, 94104
United States
Year founded
2019
Number of employees
0-100
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
